There is an ongoing Ib clinical trial testing the addition of berzosertib to radiation therapy for chemotherapy-resistant triple-negative and estrogen and/or progesterone receptor-positive, HER2-negative BC (NCT04052555), and the first results were expected by the end of 2023. This evidence concerns the gene PGR and breast cancer.